OBJECTIVE: To examine the use of oral antithrombotics (i.e., antiplatelet agents, oral anticoagulants) after myocardial infarction (MI) in the Netherlands from 1988 to 1998. METHODS: Retrospective follow-up of 3800 patients with MI, using data from the PHARMO Record Linkage System. RESULTS: From 1988 to 1998, oral antithrombotic treatment increased significantly from 54.0% to 88.9%. In 1998, only 75.8% of patients who experienced a MI in the late 1980s received oral antithrombotic treatment compared with 94.4% of those who experienced a recent MI. CONCLUSIONS: Oral antithrombotics were considerably underused in patients with a past history of MI. Therefore, these patients should be reviewed for antithrombotic therapy to assess whether their...
Background: Heart failure (HF) is associated with an increased risk of thrombotic events, which can ...
Patients who survived myocardial infarction and who are being treated with the current optimal thera...
Objective: To describe changes in medications administered to patients with acute myocardial infarct...
Objective: To determine the percentage of myocardial infarction patients in the Netherlands still us...
Aim. Primary aim was to determine the percentage of myocardial infarction patients using guideline-r...
AIMS: To assess antiplatelet use patterns after a first myocardial infarction (MI) and to evaluate t...
Background: There is good evidence that angiotensin-converting enzyme (ACE) inhibitors are beneficia...
BACKGROUND: After myocardial infarction, guidelines recommend pharmaceutical treatment with a combin...
The purpose of this study was to determine if established recommendations for treatment after myocar...
Consultant physicians and cardiologists were surveyed early in 1987 and 1989 to document the managem...
The aim of this work was to assess the quality of pharmacological treatment in patients within one y...
PURPOSE Secondary medication prevention after acute myocardial infarction (MI) is strongly recommen...
BACKGROUND: Although there are an increasing number and variety of medications available for the tre...
Item does not contain fulltextThe impact of an acute coronary syndrome (ACS) event, such as an acute...
SummaryBackgroundBoth French and international guidelines recommend long-term use of betablockers, a...
Background: Heart failure (HF) is associated with an increased risk of thrombotic events, which can ...
Patients who survived myocardial infarction and who are being treated with the current optimal thera...
Objective: To describe changes in medications administered to patients with acute myocardial infarct...
Objective: To determine the percentage of myocardial infarction patients in the Netherlands still us...
Aim. Primary aim was to determine the percentage of myocardial infarction patients using guideline-r...
AIMS: To assess antiplatelet use patterns after a first myocardial infarction (MI) and to evaluate t...
Background: There is good evidence that angiotensin-converting enzyme (ACE) inhibitors are beneficia...
BACKGROUND: After myocardial infarction, guidelines recommend pharmaceutical treatment with a combin...
The purpose of this study was to determine if established recommendations for treatment after myocar...
Consultant physicians and cardiologists were surveyed early in 1987 and 1989 to document the managem...
The aim of this work was to assess the quality of pharmacological treatment in patients within one y...
PURPOSE Secondary medication prevention after acute myocardial infarction (MI) is strongly recommen...
BACKGROUND: Although there are an increasing number and variety of medications available for the tre...
Item does not contain fulltextThe impact of an acute coronary syndrome (ACS) event, such as an acute...
SummaryBackgroundBoth French and international guidelines recommend long-term use of betablockers, a...
Background: Heart failure (HF) is associated with an increased risk of thrombotic events, which can ...
Patients who survived myocardial infarction and who are being treated with the current optimal thera...
Objective: To describe changes in medications administered to patients with acute myocardial infarct...